SELLAS Life Sciences Group, Inc. (SLS) - Dilution Analysis

10-Q filing | 172.5M shares outstanding

10-K filing | 179.6M shares outstanding

10-Q filing | 142.4M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Warrant Inducement Agreement with holders of existing warrants to purchase shares of common stock, resulting in the exercise of warrants to purchase 22,363,714 shares of common stock for gross proceeds of approximately $31.0 million. ($31.0M proceeds)

S-3 filing: This prospectus covers the offer and resale by the selling stockholders of up to an aggregate of 19,685,040 shares of common stock issuable upon the exercise of warrants to purchase shares of common stock.

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Warrant Inducement Agreement with a holder to exercise 19,685,040 shares of Common Stock at $1.20 per share, resulting in gross proceeds of approximately $23.6 million, and issued new warrants to purchase up to 19,685,040 shares of Common Stock. ($23.6M proceeds)

10-Q filing | 99.8M shares outstanding

10-K filing | 90.8M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Securities Purchase Agreement to issue and sell 8,200,000 shares of common stock and 11,485,040 pre-funded warrants, along with common warrants to purchase up to 19,685,040 shares, in a registered direct offering for gross proceeds of approximately $25.0 million. ($25.0M proceeds)

10-Q filing | 68.3M shares outstanding

10-Q filing | 64.3M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. completed a registered direct offering on August 1, 2024, issuing 6,370,070 shares of common stock and 9,478,986 pre-funded warrants, along with common warrants to purchase up to 15,849,056 shares, for gross proceeds of approximately $21.0 million. ($21.0M proceeds)

10-Q filing | 57.8M shares outstanding

S-3/A filing: This is an S-3/A filing related to a shelf registration, detailing terms for various securities, including potential convertibles to common stock, denominations, and payment provisions.

S-3 filing: Registration for resale of 13,029,316 shares of common stock by selling stockholders, issuable upon exercise of warrants.

S-3 filing: SELLAS Life Sciences Group files an S-3 form to offer shares of its common stock and preferred stock and debt securities for a total dollar amount of $200,000,000.

10-K filing | 56.3M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Securities Purchase Agreement to issue and sell 11,000,000 shares of common stock at $1.535 per share and 2,029,316 pre-funded warrants at $1.5349 per warrant, with aggregate gross proceeds expected to be approximately $20.0 million. ($20.0M proceeds)

8-K filing: SELLAS Life Sciences Group, Inc. completed an offering of 10,130,000 shares of common stock and 1,870,000 pre-funded warrants, along with common warrants to purchase up to 12,000,000 shares, for gross proceeds of approximately $9.0 million. ($9.0M proceeds)

10-Q filing | 32.1M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell 3,100,000 shares of common stock and 552,300 pre-funded warrants, along with common warrants to purchase up to 3,652,300 shares, at a combined offering price of $1.0952 per share/warrant, expecting gross proceeds of approximately $4.0 million. ($4.0M proceeds)

10-Q filing | 28.3M shares outstanding

10-Q filing | 28.3M shares outstanding

10-K filing | 28.3M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. closed its underwritten offering of 7,220,217 shares of common stock and warrants to purchase up to 7,220,217 shares of common stock, resulting in net proceeds of approximately $18.5 million. ($18.5M proceeds)

10-Q filing | 20.6M shares outstanding

10-Q filing | 20.3M shares outstanding

10-Q filing | 20.5M shares outstanding

10-K filing | 15.5M shares outstanding

10-Q filing | 15.9M shares outstanding

10-Q filing | 15.3M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. had approximately $32.0 million of cash and cash equivalents and 15,873,941 shares of common stock outstanding as of July 6, 2021, including 421,102 shares sold subsequent to June 1, 2021 at an average price of $13.15 per share for net proceeds of approximately $5.4 million. ($5.4M proceeds)

8-K filing: The company issued and sold 365,825 shares of its common stock under an "at-the-market" offering program for aggregate net sale proceeds of approximately $3.81 million, after deducting sales commissions since April 16, 2021. ($0.0M proceeds)

10-Q filing | 15.1M shares outstanding

S-3 filing: SELLAS Life Sciences Group, Inc. files an S-3 form to offer and sell up to an aggregate amount of $150,000,000 of any combination of common stock, preferred stock, and debt securities from time to time. Additionally, they will offer common stock up to $50,000,000 through an at-the-market offering.

10-K filing | 15.1M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Share Purchase Agreement to issue and sell 2,320,000 shares of common stock at $7.00 per share in a registered direct offering, and warrants to purchase 2,412,632 shares of Common Stock were exercised at a weighted average exercise price of $3.35 per share. ($24.3M proceeds)

10-Q filing | 9.5M shares outstanding

S-3 filing: SELLAS Life Sciences Group, Inc. is registering the resale of up to 5,488,156 shares of common stock by selling stockholders, including shares issuable upon exercise of warrants.

10-Q filing | 9.5M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a securities purchase agreement to sell 2,744,078 shares of common stock and warrants to purchase up to 2,744,078 shares of common stock at a price of $3.335 per share and warrant, with gross proceeds expected to be approximately $9.2 million. ($9.2M proceeds)

S-1 filing: This prospectus relates to the resale of up to 818,900 shares of our common stock issuable upon exercise of certain outstanding warrants issued by us in a private placement.

10-Q filing | 6.7M shares outstanding

10-K filing | 6.7M shares outstanding

8-K filing: SELLAS Life Sciences Group, Inc. entered into a Securities Purchase Agreement to issue and sell 1,189,000 shares of common stock at $3.9825 per share and 448,800 pre-funded warrants at $3.9725 per Pre-Funded Warrant, along with warrants exercisable for 818,900 shares of Common Stock at an exercise price of $3.93 per share in a concurrent private placement. ($6.52M proceeds)